Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis.
about
Antimicrobial resistance surveillance in urinary tract infections in primary care.Ten years of antibiotic consumption in ambulatory care: trends in prescribing practice and antibiotic resistance in AustriaSusceptibility of urinary tract bacteria to fosfomycinRisk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infectionsCefditoren: Comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatientsIncreasing ciprofloxacin resistance of isolates from infected urines of a cross-section of patients in Karachi.Occurrence of Antimicrobial-Resistant Escherichia coli and Salmonella enterica in the Beef Cattle Production and Processing Continuum.Eravacycline (TP-434) is efficacious in animal models of infection.Change of antimicrobial susceptibility among Escherichia coli strains isolated from female patients with community-onset acute pyelonephritis.Determinants of quinolone versus trimethoprim-sulfamethoxazole use for outpatient urinary tract infectionComparative effectiveness of different oral antibiotics regimens for treatment of urinary tract infection in outpatients: an analysis of national representative claims databaseGlobal fluoroquinolone resistance epidemiology and implictions for clinical use.Has the emergence of community-associated methicillin-resistant Staphylococcus aureus increased trimethoprim-sulfamethoxazole use and resistance?: a 10-year time series analysis.Comparison of computed tomography findings between bacteremic and non-bacteremic acute pyelonephritis due to Escherichia coli.Recommended Initial Antimicrobial Therapy for Emphysematous Pyelonephritis: 51 Cases and 14-Year-Experience of a Tertiary Referral Center.Fluoroquinolone-Resistant and Extended-Spectrum β-Lactamase-Producing Escherichia coli Infections in Patients with Pyelonephritis, United States(1).Prevalence and risk factor analysis of resistant Escherichia coli urinary tract infections in the emergency department.Optimizing empiric antibiotic therapy in patients with severe β-lactam allergy.Crystal Structures of Trimethoprim-Resistant DfrA1 Rationalize Potent Inhibition by Propargyl-Linked Antifolates.Management of complicated urinary tract infections in the era of antimicrobial resistance.The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens.Levofloxacin for the treatment of pyelonephritis.A clinical decision rule identifies risk factors associated with antimicrobial-resistant urinary pathogens in the emergency department: a retrospective validation study.Clinical and Molecular Characterization of Community-Onset Urinary Tract Infections Due to Extended-Spectrum Cephalosporin-Resistant Enterobacteriaceae.Escherichia coli antibiotic resistance in emergency departments. Do local resistance rates matter?The Rise of Fluoroquinolone-Resistant Escherichia coli in the Community: Scarier Than We Thought.The association of antimicrobial resistance with cure and quality of life among women with acute uncomplicated cystitis.Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department.Alterations of growth rate and gene expression levels of UPEC by antibiotics at sub-MIC.Clinical implications of healthcare-associated infection in patients with community-onset acute pyelonephritis.Phylogenetic relationships, biofilm formation, motility, antibiotic resistance and extended virulence genotypes among Escherichia coli strains from women with community-onset primitive acute pyelonephritis.Risk factors for aquiring multidrug-resistant organisms in urinary tract infections: A systematic literature review.ncy ID NET: Review of a 20-Year Multisite Emergency Department Emerging Infections Research Network
P2860
Q30249261-DF1E8364-A37B-420C-B501-01FD5C618403Q33445317-94A06EE0-61ED-4B72-9E38-F133FF002BD2Q33494283-F34494B5-FD2A-427E-99F1-6E8BA5CFEFF0Q34233075-961FE304-F65F-4624-8AA5-66E778CCF2C0Q34420965-9689D0EE-82F8-426F-8275-36B051191CFFQ34523193-1AE13674-E774-4D1E-9D0D-286FEDBD4D5BQ34777654-942E5D14-12BD-4EF1-AD1C-D2E4BC43495FQ35385590-DCF78607-316E-405B-90F0-9F2EDAB329A0Q35648288-9DEF69F7-3229-469A-908D-EE1C89B1BF65Q35806315-DA40D2C9-71B3-4659-BA72-C8F231634FFCQ36153920-DD93C3D7-E440-4463-A936-84462D64CED8Q36337074-405EE35D-F313-438E-9035-104C89213BD5Q36364141-1C782AD5-8928-474E-9423-B1AF283132B0Q36823628-B703DAE7-5971-4030-8C7E-D9E4694523D7Q36992856-CA348E92-6835-40FC-9E47-B2752B96DF07Q37196254-F518589E-35AB-4266-A64B-EBD6ED637D1FQ37233393-3DB28014-C9CD-460F-9965-50FF3C538FC8Q37335712-A01FD759-6465-490D-A3D3-C962742D3A5CQ37412310-FE3C3075-B112-4295-9D1A-A0848272B7ABQ37810405-CA0C2D11-198B-496B-A450-4FB1B87A6420Q37952621-F7380A42-ACFE-41FC-A30B-F3000F9FD555Q38101380-263357B5-FD0D-42EB-A3E9-C22C585A6C13Q38385794-C390529D-0D6E-4E8E-89AD-73B72F028D6AQ40525399-BCCEC903-306C-4865-9681-7F1BC680C2ADQ41691397-76EEAE70-DEBE-4428-9F00-FE5FB7A0BBA2Q43160364-35703B71-775C-4B1E-9614-3619B1F017A8Q43676292-1EB11D77-DF1C-45C1-B05C-48A080B979D7Q48158622-730AE0C8-DB88-4F9C-BAAD-5A5543DA1C98Q48256161-B179FC39-E0B1-4D55-A9B8-2CAA8F51FB7FQ54364286-A9EE5EA2-32BF-42B0-9376-03E7B71C7F2DQ54969822-E573158A-7390-4539-9560-322E3FB19F8FQ55493627-58BDC7AA-0D1B-4F28-B474-CA1DC17BD249Q57104240-3FBEF168-98D4-4FCD-B44A-8DCB1E211D13
P2860
Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Prevalence and risk factor ana ...... patients with pyelonephritis.
@en
Prevalence and risk factor ana ...... patients with pyelonephritis.
@nl
type
label
Prevalence and risk factor ana ...... patients with pyelonephritis.
@en
Prevalence and risk factor ana ...... patients with pyelonephritis.
@nl
prefLabel
Prevalence and risk factor ana ...... patients with pyelonephritis.
@en
Prevalence and risk factor ana ...... patients with pyelonephritis.
@nl
P2093
P2860
P356
P1476
Prevalence and risk factor ana ...... patients with pyelonephritis.
@en
P2093
Anusha Krishnadasan
David A Talan
EMERGEncy ID NET Study Group
Fredrick M Abrahamian
Gregory J Moran
Walter E Stamm
P2860
P304
P356
10.1086/592250
P407
P577
2008-11-01T00:00:00Z